MELANOMA STAGE IV

This phase 2 trial tests the immunotherapy drug nivolumab (Opdivo) given before and after surgery for people with stage III or IV melanoma. The goal is to see if tailoring treatment based on tumor biomarkers leads to better outcomes. About 90 participants will be enrolled at a si…

This early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help th…

This early-phase trial is testing a new treatment called VET3-TGI, a virus engineered to attack cancer cells. It is given alone or with the immunotherapy drug atezolizumab to up to 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals…

This early-phase trial tests whether giving different drug combinations after surgery, based on how well the tumor responded to initial treatment, can reduce the risk of melanoma returning. About 50 adults with stage III or IV BRAF-mutant melanoma will receive encorafenib, binime…

This early-phase study tests a personalized cell therapy for people with several types of advanced cancer that have spread and express a protein called NY-ESO-1. Participants receive a single infusion of their own immune cells that have been genetically modified to recognize and …

This study tests whether adding a low-dose chemotherapy drug (cyclophosphamide) to an immunotherapy (pembrolizumab) can shrink tumors in people with advanced melanoma that has stopped responding to standard immunotherapy. About 14 adults with stage III or IV melanoma that cannot …

This study tests whether combining two drugs, binimetinib and imatinib, can shrink tumors in people with advanced KIT-mutant melanoma that cannot be surgically removed. About 25 adults with stage III or IV melanoma will receive the drug combination. The goal is to see how many pa…

This study is for people with high-risk melanoma who have tiny bits of tumor DNA still in their blood after surgery. It compares a two-drug immunotherapy combo against a single drug to see which better clears these hidden cancer cells. About 54 participants will be randomly assig…

This study tests a combination of three immunotherapy drugs (IL2, ipilimumab, and nivolumab) in people with advanced melanoma that can't be removed by surgery and has stopped responding to prior anti-PD1 treatment. The goal is to see if this new approach can shrink tumors or slow…

This study compares two treatments for people with advanced melanoma that has spread to the brain. One group gets standard immunotherapy drugs (ipilimumab and nivolumab) alone, while the other group also receives targeted radiation to brain tumors. The goal is to see if adding ra…

This study tests a new treatment called [212Pb]VMT01, which delivers targeted radiation to melanoma cells. It is for people with advanced melanoma that has not responded to prior treatments. The study will see if this therapy is safe and effective when used alone or with another …

This study looks at 24 people with advanced melanoma who are starting immunotherapy. Researchers will do a special PET/CT scan and a blood test for tumor DNA about 3-4 weeks after the first treatment. The goal is to see if these early tests can predict whether the immunotherapy i…

This study looks at whether beta-glucan, a natural fiber from yeast, can improve the immune response to the immunotherapy drug pembrolizumab in people with stage III or IV melanoma. Researchers will measure changes in immune cells from blood samples. The goal is to understand how…

This study follows about 40 people who received Miltenyi CAR T cell therapy at least one year ago. Researchers will track side effects, overall health, and any return of cancer. The goal is to understand the long-term safety of this treatment.